Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Single Versus Repeated Intravenous Oncolytic Virus Infusions
View:
Post by spesestsemper on Sep 28, 2024 3:08pm

Single Versus Repeated Intravenous Oncolytic Virus Infusions

Single Versus Repeated Intravenous Oncolytic Virus Infusions: Implications for Rationalised Scheduling of Therapy in Hepatocellular Carcinoma. | medRxiv

Karen J Scott, Emma West, Rebecca Brownlie, Fay Ismail, Christy Ralph, Matt Coffey, Alan A Melcher, Alison Taylor, Salvatore Papa, Adel Samson
Comment by spesestsemper on Sep 28, 2024 6:44pm
Interesting enough the slot just above oncolytics at the ov conference Program & sponsors - IOVC2024 is this A Novel Oncolytic Virus VG161: Efficacy of A Multicenter Phase I Clinical Trial for Late-Stage Hepatocellular Carcinoma Patients (by William Jia)
Comment by Buckhenry on Sep 29, 2024 6:27pm
I get all gitty and pull out the sears Christmas wish book when I hear unnoteable telling us about all these biotechs doing so well as oncy approaches a 52 year... I mean week... low...
Comment by Buckhenry on Sep 30, 2024 11:52am
The market and pharmaceuticals can't or more importantly....see the value of ur posts unnoteable 
Oncolytics Biotech Inc
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Dealroom for high-potential pre-IPO opportunities